A note on improvement in Dermatology Life Quality Index (DLQI) among patients with hidradenitis suppurativa treated with adalimumab

Hidradenitis suppurativa Research


Author(s): Thomsen SF

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with profound negative impact on quality of life. Adalimumab (anti-TNF) is indicated for moderate-to-severe HS unresponsive to conventional therapy. Herein, studies of the change in Dermatology Life Quality Index (DLQI) among patients with HS treated with adalimumab are reviewed. The anticipated gain in DLQI is only modest in patients with HS treated with adalimumab, even in trials of high quality, and does not exceed the established minimal clinically important difference. Biologics targeting other inflammatory cytokines are warranted in the treatment of HS.


Dermatology Journal and/or Publisher

Journal Name: The Journal of dermatological treatment
Journal Abbreviation: J Dermatolog Treat
Journal Date Published:


National Center for Biotechnology Information

PMID: 29671663
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/29671663
Lasted Revision: 2018-04-19


Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).


Tags:
0 Comments

Leave a reply

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2018 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Log in with your credentials

Forgot your details?